This stock has historically been a consistent performer. Current levels look like a great entry point but am skeptical. Executive management unloaded shares over the past 6-9 months and then most recent numbers came back negative. CFO cashed out of his position and then announced his retirement. Recent posts on pharma/med device sale rep forum talk about an announcement of layoffs at access vascular oncology division and the loss of an important acquisition. Does anyone know if there are layoffs at Bard and what happened with failed acquisition? Was future guidance based in part on that acquisition? I currently don't hold a position with this stock but am considering one.